In Vitro Clot Trapping Efficiency of the FDA Generic Inferior Vena Cava Filter in an Anatomical Model: An Experimental Fluid-Structure Interaction Benchmark.

PURPOSE: Robust experimental data for performing validation of fluid-structure interaction (FSI) simulations of the transport of deformable solid bodies in internal flow are currently lacking. This in vitro experimental study characterizes the clot trapping efficiency of a new generic conical-type inferior vena cava (IVC) filter in a rigid anatomical model of the IVC with carefully characterized test conditions, fluid rheological properties, and clot mechanical properties. METHODS: Various sizes of spherical and cylindrical clots made of synthetic materials (nylon and polyacrylamide gel) and bovine blood are serially injected into the anatomical IVC model under worst-case exercise flow conditions. Clot trapping efficiencies and their uncertainties are then quantified for each combination of clot shape, size, and material. RESULTS: Experiments reveal the clot trapping efficiency increases with increasing clot diameter and length, with trapping efficiencies ranging from as low as approximately 42% for small 3.2 mm diameter spherical clots up to 100% for larger clot sizes. Because of the asymmetry of the anatomical IVC model, the data also reveal the iliac vein of clot origin influences the clot trapping efficiency, with the trapping efficiency for clots injected into the left iliac vein up to a factor of 7.5 times greater than that for clots injected into the right iliac (trapping efficiencies of approximately 10% versus 75%, respectively). CONCLUSION: Overall, this data set provides a benchmark for validating simulations predicting IVC filter clot trapping efficiency and, more generally, low-Reynolds number FSI modeling.

Chemoprevention of breast cancer and the trials of the National Surgical Adjuvant Breast and Bowel Project and others.

The idea of breast cancer prevention by hormonal means stemmed from the results of treatment trials, many of them carried out by the National Surgical Adjuvant Breast and Bowel Project (NSABP). Over the years, a number of NSABP treatment studies demonstrated that breast cancer recurrence was reduced in women with the disease who were given tamoxifen, a selective estrogen receptor (ER) modulator (SERM). Five subsequent tamoxifen prevention trials with this agent have shown a 48% reduction in ER-positive cancers, but no effect for ER-negative cancers, and an increase in endometrial cancer and thromboembolic events. The drug raloxifene, another SERM, originally examined as an osteoporosis agent, has also shown promise for the prevention of breast cancer, although, as with tamoxifen, the drug carries a risk for thromboembolic events. There is recent evidence in a large treatment trial that the aromastase inhibitor anastrazole, a 'pure anti-estrogen', holds promise as a breast cancer preventive agent. Longer follow-up and the testing of additional agents is required before these drugs can be used widely for prevention. In addition, future research should focus on the identification of at-risk women who can perhaps be targeted for specific prevention agents.

The role of oral etoposide in non-small cell lung cancer.

Oral etoposide has been tested alone and in combination in a number of tumour types since the late 1980s because of its mild toxicity, high response rates, ease of administration, and comparatively low cost. Encouraging early results with protracted oral etoposide therapy in small cell lung cancer have not been borne out in non-small cell lung cancer (NSCLC), particularly in the advanced-disease setting. However, in stage IV NSCLC, oral etoposide does appear to be as compatible with most of the newer agents as it has been with platinum compounds; these combinations continue to be explored, although they have not penetrated into standard usage. In stage III NSCLC, large combined-modality studies are ongoing. Other investigations examining protracted administration in combination with radiation 'sensitisers' are planned. It is possible that by exploiting the 'radiosensitising effect' of prolonged low dose oral etoposide, combined with that of other proven radiosensitisers such as paclitaxel, gemcitabine, and topotecan, we may identify a niche for oral etoposide in the future.

The effect of clinical history on chest radiograph interpretations in a PACS environment.

The effect that accompanying patient information has on diagnostic accuracy in radiologic interpretation has been studied by many researchers but remains a matter of contention. Experiments in the past emphasized the chest film because this procedure is the one done most frequently in radiology. However, with the increasing importance of digital imaging, the role of patient history in these procedures should be assessed. The use of a model computerized patient history in the interpretation of digitized chest images that were displayed on a high-resolution workstation was studied. Two hundred forty-seven selected posteroanterior chest images that indicated disease and that indicated no disease were interpreted in random sequence by five board-certified radiologists, with and without accompanying patient histories. Readers were prompted by the response forms to evaluate images for the possible occurrence of interstitial diseases, nodules, or pneumothorax. No significant differences (P = .05) in the detection of these abnormalities were noted between case readings with and without history for any of the radiologists or for the group as a whole. However, this methodology reflects a direct interpretation approach. The results of this study may not necessarily be applicable to individual prompts, different imaging procedures, or other abnormalities.

Simultaneous mass spectrometry and thermoconductivity measurements of end-tidal xenon concentrations: a comparison.

Studies in which the rate of local cerebral blood flow is determined by xenon-enhanced computerized tomography require measurement of end-tidal gas. A mass spectrometer and a thermoconductivity detector were compared in measuring the concentration of xenon in end-tidal gas both in humans and in a clinically simulated ("breathing bag") system. The experiments showed that the two instruments provided virtually identical results up to a rate of 18 breaths/min, at which rate recorded concentrations showed marginal degradation with the thermoconductivity detector. Given the absence of a significant difference in the ability of the mass spectrometer and the thermoconductivity detector to measure end-tidal xenon concentration, the thermoconductivity detector appears to be a satisfactory alternative in studies measuring the rate of local cerebral blood flow by enhanced computerized tomography.

Stable xenon CT blood flow mapping for evaluation of patients with extracranial-intracranial bypass surgery.

Xenon computerized tomography (Xe CT) blood flow studies were conducted in 25 patients referred for a possible extracranial-intracranial bypass procedure for occlusive vascular disease in one or more extra- or intracranial vessels. These studies were helpful in selecting eight candidates for surgery. The Xe CT studies were performed at one or two brain levels using a prototype Xe CT system for measurement of cerebral blood flow which was designed in collaboration with the General Electric Co., and adapted for the GE 9800 scanner. In those patients selected to undergo operation, Xe CT demonstrated compromise of flow reserve regionally, globally, and/or in the watershed area. All eight patients who underwent the procedure showed a favorable clinical response postoperatively, and seven had a dramatic increase in flow. The 17 patients whose baseline CT studies showed no reduction of flow with the Xe CT method were not selected for surgery. All 25 patients have remained neurologically stable to date. Case studies of three of the eight patients undergoing bypass surgery are presented. This limited but consistent experience suggests that Xe CT blood flow mapping makes possible the recognition of brain regions in which flow reserves are compromised. This is due to the relatively high degree of spatial resolution that this technique provides and to the fact that mapping can be correlated directly with the anatomy. Used in combination with a careful clinical examination and an accurate medical history, this study method appears to be a useful guide in the selection of patients who are most at risk from hemodynamic instability and those who are most likely to benefit from flow-augmentation surgery.

Small-cell lung cancer: a perspective on the past and a preview of the future.

Despite advances in the treatment of small-cell lung cancer during the 1970s, with the use of combination chemotherapy, and in the 1980s, with the combination of etoposide and cisplatin plus concurrent radiation therapy, treatment success seems to have reached a plateau in the current decade. Research should now be directed into three areas: (1) strategies to prevent the development of second cancers, one of the major causes of death in people "cured" of their first primary cancer; (2) introduction of new agents such as paclitaxel (Taxol) and other newer chemotherapeutic drugs into clinical trials, particularly in conjunction with radiation therapy in limited disease; and (3) development of new therapeutic approaches, such as the modulation of drug resistance, molecular biology interventions, and monoclonal antibody therapy, strategies that are based on increased understanding of small-cell lung cancer biology. Although it is doubtful that any single strategy will be curative, selective approaches that exploit new research findings in conjunction with moderately effective, more conventional treatments might allow us to raise remission and survival rates significantly.

Premature menopause after cancer treatment.

PURPOSE: The purpose of this report is to examine the impact that cancer therapies have on ovarian function. OVERVIEW: Symptoms of and conditions due to estrogen deficiency after cancer therapy are described, and interventions are proposed. The consequences of short-term as well as prolonged estrogen deficiency-including vasomotor instability, infertility, genitourinary atrophy, coronary artery disease, and osteoporosis-are discussed. CLINICAL IMPLICATIONS: Symptoms and conditions associated with premature menopause may cause additional stress for women who undergo cancer therapy. Knowledge about what happens to these women can enable healthcare providers to help them make decisions about cancer treatment, engage in self-care activities, and explore options for preserving fertility.

Local cerebral blood flow alterations (Xe-CT method) in an accident victim.

Computed tomography was used before and during inhalation of nonradioactive xenon gas to measure and map local cerebral blood flow noninvasively at two PaCO2 levels in a 19-year-old accident victim. The technique demonstrated normal response to elevated PaCO2 with only a regional loss of autoregulation.

Xenon/CT blood flow mapping of the kidney and liver.

A noninvasive technique for measuring blood flow by xenon-enhanced X-ray transmission CT has been developed and reported quite extensively in recent years. In this method nonradioactive xenon gas is inhaled, and the temporal changes in radiographic enhancement produced by the inhalation are measured by sequential CT. Time-dependent xenon concentration within various tissue segments is used to derive local blood flow maps. The method has been amply discussed in relation to assessment of local cerebral blood flow. Its application to other body organs is explored in this paper, in which results from six preliminary blood flow studies in the liver and kidneys of nonhuman primates are reported. Blood flow in renal cortex ranged from 150 to 280 ml/100 cc/min and hepatic tissue perfusion from 80 to 120 ml/100 cc/min. The advantages and limitations of the method in such applications are discussed.

Mapping cerebral blood flow by xenon-enhanced computed tomography: clinical experience.

Local cerebral blood flow was measured and mapped using xenon-enhanced x-ray transmission computed tomography. Studies involving 4-6 minutes of xenon-oxygen inhalation can be performed routinely in awake and anesthetized patients with acceptable patient tolerance and compliance. Several case studies of patients with acute and chronic ischemic injuries and other cerebral abnormalities are presented to illustrate characterization of flow pattern in normal and abnormal tissue, as well as the relevance of this flow information to clinical patient management.

Does knowledge of the clinical history affect the accuracy of chest radiograph interpretation?

To examine the effect that a concise, objective, and potentially computer-extractable history would have on diagnostic accuracy in the interpretation of chest radiographs, we designed and tested a computerized patient-history form that could be integrated realistically into the clinical environment. We performed a series of studies in which 247 posteroanterior normal (79) and abnormal (168) chest radiographs were interpreted by four board-certified radiologists, both with and without accompanying clinical histories. The radiologists recorded their confidence rating of the presence or absence of one or more of the following abnormalities: interstitial disease, nodule, and pneumothorax. Analysis of receiver operating characteristics showed that, with the exception of interpretation of one abnormality by one radiologist, there were no statistically significant differences (p less than .05) between cases interpreted with and without the history form for any of the radiologists. The results of our study suggest that knowledge of clinical history does not affect the accuracy of chest radiograph interpretations for the detection of interstitial disease, nodules, and pneumothoraces. These results may not be applicable to other clinical situations.